Breast Cancer: 26 percent less risk if menopausal hormone therapy plus vitamin D

Created September 2015

Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.

Am J Clin Nutr. 2015 Sep 9. pii: ajcn104323. [Epub ahead of print]

Cadeau C1, Fournier A1, Mesrine S1, Clavel-Chapelon F1, Fagherazzi G1, Boutron-Ruault MC2.

Data based on questionnaire Vitamin D and Calcium dose size is not specified See also VitaminDWiki * Overview Breast Cancer and Vitamin D contains the following summary and sections {include} See also web * Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study 2008 * Clipped from abstract “The association was stronger in women never using menopausal hormone therapy (HT) compared with past and current users” * * *📄 Download the PDF from VitaminDWiki* *

BACKGROUND:

Experimental studies suggest protective effects of vitamin D on breast carcinogenesis, particularly on estrogen receptor-positive tumors. Epidemiologic data are less conclusive.

OBJECTIVE:

Our objective was to investigate the association between postmenopausal breast cancer risk and current or past vitamin D supplementation overall and according to the use of menopausal hormone therapy (MHT).

DESIGN:

Between 1995 and 2008, 2482 invasive breast cancer cases were diagnosed among 57,403 postmenopausal women from the E3N prospective cohort during 581,085 person-years . Vitamin D supplementation was assessed from biennially self-administered questionnaires sent in 1995, 2000, 2002, and 2005 and from medico-administrative data on drug reimbursements since 2004. Multivariable HRs for primary invasive breast cancer and 95% CIs were estimated by using Cox models.

RESULTS:

A decreased postmenopausal breast cancer risk was associated with current (HR: 0.82; 95% CI: 0.69, 0.97) but not past (HR: 1.10; 95% CI: 0.92, 1.31) vitamin D supplementation (P-homogeneity = 0.02). The association with current vitamin D supplementation differed according to MHT use: ever users (HR: 0.74 ; 95% CI: 0.60, 0.90) and never users (HR: 1.13; 95% CI: 0.89, 1.56); P-homogeneity = 0.02.

CONCLUSIONS:

In this observational study, current vitamin D supplementation, mostly taken daily and combined with calcium, was associated with a decreased postmenopausal breast cancer risk in MHT users. These findings should be confirmed before considering vitamin D supplementation to partly balance the MHT-associated increased breast cancer risk.

PMID: 26354532

Publisher wants $40 for the PODF

Tags: Breast Cancer